Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions
about
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responsesComparative expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells infected with human immunodeficiency virus (HIV-1)Poxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenDeletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-CVaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of PlasmodiumA human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virusDendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensUse of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individualsMicroRNA regulation and its effects on cellular transcriptome in human immunodeficiency virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell countsImproving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysVirological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve ImmunogenicityRodent models for HIV-associated neurocognitive disorders.Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in miceComparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicityDeletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cellsAttenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.Enhancing poxvirus vectors vaccine immunogenicity.High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.Clinical applications of attenuated MVA poxvirus strain.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciA Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.The Gene of Goatpox Virus Encodes an Inhibitor of NF-κB and Apoptosis and May Serve as an Improved Insertion Site To Generate Vectored Live Vaccine
P2860
Q21135240-1D2A63F7-3422-432D-B2BD-BFED0A7311AEQ21560946-43AAA932-3443-4660-A706-0CF03E8AC1BCQ26995078-AFD0F861-39CD-426A-809F-A2C89823DD7EQ26995905-3FABECF7-8066-4503-9F89-27B8ED969329Q27302081-ED7D21C6-F040-4463-BFAD-019EEF31F77DQ27306437-460565CB-32B5-42D2-8075-8F4B73062C19Q28730541-1E6E8A9B-06F8-468B-BED0-CEDBDEBF4311Q31037728-FD61912F-99C2-4CAF-99EC-CF22166F772BQ33916776-EC9A7B64-466B-485E-805C-07EFF0059137Q34182371-A94A4828-8921-4A28-BD2F-2BDBCB09B8E5Q34247289-4836279B-6D87-4409-9EA6-FC7446271E51Q34274515-7DA4EF39-0751-4373-B19F-395D7BB39FC0Q34310410-8C57A452-CC82-4922-9515-7DB162BF1C0AQ34465228-DE75B757-A216-4C85-8B7A-8A7FCF5FD0A3Q34630184-F50DC0E7-0D54-4E6C-BE6C-F6BB72BECB84Q34747583-06171C78-E7C7-47DB-BF7C-CF305918AC65Q34796206-0F04E1DB-81F1-4175-8868-1815C412287EQ34991112-8A2CF16F-81D9-4F05-888B-46E41EDA5E1DQ35656345-AE1EAA12-2822-46B2-B03E-FF93D1B7F2D4Q35803957-1D781344-1C0B-422C-B771-0A05D3699F13Q35943846-9BA4B1BB-3BB9-4244-B2CC-6C38410478E6Q36155548-DDF1995A-63B2-495A-8AF1-A774DF9B58CAQ36397581-A2F0B8AE-3F19-4D0B-AF33-99D9B6D49B0CQ36741144-1F327A50-6570-4912-A429-9058B72A7022Q36911682-A8C36F0F-E391-448B-A233-BCF755E27CA1Q36978452-51440E6D-5ABB-4DE4-8489-5789AF7C9D13Q36978998-AAE2D35B-BBAD-44F5-8BF6-B1C053491192Q37255121-FA5D9278-5475-4BB0-A353-8ECAD68271C0Q37308720-D79B733E-DB4C-4ED9-842F-9DBC155A3A57Q37643731-80190455-9C11-412B-9509-166FF4584E58Q37643733-D8CF3970-9802-40DF-9AB0-8E745A7CFF82Q38156198-ACB2C5FE-C9D4-4313-A201-36A92ED4111EQ38415577-4BFEE189-3499-4EB7-99C4-C94A89C00CA1Q38725610-2091BC3F-DF07-47CD-99C9-8E683F00C3E1Q40071705-F8209BB7-3ADB-489B-9ED0-519F398D1C0CQ40339467-484717B6-C8B2-49B8-9E33-E025CE02926EQ40919787-F45629D7-CFF7-4B6F-A4DD-BC1262952BCAQ47252143-EA81632A-5987-4856-B642-67352FC343ABQ51784219-85616C07-6000-4B83-ADCF-FDA6D47A047BQ56556724-A559B9DA-F828-4E3D-88D5-67509A9DFC6F
P2860
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunogenic profiling in mice ...... ion by specific gene deletions
@ast
Immunogenic profiling in mice ...... ion by specific gene deletions
@en
Immunogenic profiling in mice ...... ion by specific gene deletions
@nl
type
label
Immunogenic profiling in mice ...... ion by specific gene deletions
@ast
Immunogenic profiling in mice ...... ion by specific gene deletions
@en
Immunogenic profiling in mice ...... ion by specific gene deletions
@nl
prefLabel
Immunogenic profiling in mice ...... ion by specific gene deletions
@ast
Immunogenic profiling in mice ...... ion by specific gene deletions
@en
Immunogenic profiling in mice ...... ion by specific gene deletions
@nl
P2860
P50
P3181
P1433
P1476
Immunogenic profiling in mice ...... ion by specific gene deletions
@en
P2093
José Luis Nájera
Juan García-Arriaza
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0012395
P407
P577
2010-01-01T00:00:00Z